Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance

Aims To evaluate the number and nature of reported congenital malformations (CMs) after intrauterine exposure to non‐tumour necrosis factor inhibitor biologics (non‐TNFi biologics) compared to certolizumab pegol (CZP). Methods A retrospective comparative study was conducted in the EudraVigilance (EV...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2022-12, Vol.88 (12), p.5378-5388
Hauptverfasser:	Ghalandari, Nafise, Crijns, Hubertina J. M. J., Bergman, Jorieke E. H., Dolhain, Radboud J. E. M., Puijenbroek, Eugène P., Hazes, Johanna M. W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - drug therapy autoimmune diseases Biological Products - adverse effects Certolizumab Pegol - adverse effects EudraVigilance database Humans Interleukin 1 Receptor Antagonist Protein - therapeutic use Necrosis non‐TNFi biologics Original pregnancy Retrospective Studies Rituximab - therapeutic use Tumor Necrosis Factor-alpha Ustekinumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!